Piperazin-2-one → 4-((2-Bromo-5-(trifluoromethyl)phenyl)sulfonyl)piperazin-2-one
반응식
[NH:1]1[CH2:6][CH2:5][NH:4][CH2:3][C:2]1=[O:7].[Br:8][C:9]1[CH:14]=[CH:13][C:12]([C:15]([F:18])([F:17])[F:16])=[CH:11][C:10]=1[S:19](Cl)(=[O:21])=[O:20]>>[Br:8][C:9]1[CH:14]=[CH:13][C:12]([C:15]([F:17])([F:16])[F:18])=[CH:11][C:10]=1[S:19]([N:4]1[CH2:5][CH2:6][NH:1][C:2](=[O:7])[CH2:3]1)(=[O:21])=[O:20]참가 물질
3
실험 절차
The title compound was prepared in a manner similar to that described for Intermediate EU using piperazin-2-one and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. 1H NMR (400 MHz, CDCl3) δ 8.43-8.35 (d, J=2.3, 1H), 7.99-7.89 (d, J=8.2, 1H), 7.77-7.65 (dd, J=8.3, 2.3, 2H), 6.95 (s, 2H), 3.99 (s, 3H), 3.73-3.58 (t, J=5.3, 3H), 3.51-3.42 (m, 3H), 1.36-1.04 (m, 1H).
출처 및 근거
- ORD 기록
- ord-ea9f2db7931146e49993f7d322a6b731
- 출처 데이터셋
- uspto-grants-2015_07
- 특허 번호
- US09079866B2
반응 노트
불러오는 중…